Please ensure Javascript is enabled for purposes of website accessibility

Why Inogen Shareholders Are Having Another Tough Day

By Brian Feroldi - Updated Aug 7, 2019 at 2:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares sink after the medical-device maker reported weak second-quarter results and slashed guidance. Again.

What happened

After Inogen (INGN 3.53%), a medical device company focused on repository care, reported ugly second-quarter results and lowered its guidance, its shares dropped 23% as of 2:12 p.m. EDT on Wednesday.

So what

The headline numbers were pretty unattractive: 

  • Revenue grew 4%, to $101.1 million. That was well below the $106.8 million that Wall Street was expecting.
  • Gross margin dipped 10 basis points, to 49.7%.
  • Operating expenses jumped 11%, to $38.1 million. 
  • Net income dropped 30%, to $10.2 million, or $0.45 per share. That was below the $0.49 that analysts were expecting.

Management doesn't see this trend reversing itself anytime soon, either. Revenue is even expected to decline in the third quarter of 2019. 

Businessman sitting in front of a laptop and making the thumbs down gesture with his right hand.

Image source: Getty Images.

To make matters worse, management cut its full-year guidance for the second quarter in a row:

  • Total revenue is now expected to land between $370 million and $375 million, down from its prior outlook of $405 million to $415 million. Wall Street was expecting $408.9 million in total revenue.
  • Net income is now expected to land between $26 million and $28 million. That's down from its prior range of $36 million to $38 million.

CEO Scott Wilkinson said that "the level of sales representative attrition was higher than expected as many of the representatives hired in 2018 were unable to meet our sales targets."

Management also announced it's acquiring a company called New Aera, which makes portable non-invasive ventilators, for $70.4 million in cash and up to $31.4 million in potential earnouts.

Traders mauled the stock in response to the weak results, surprise acquisition, and guidance cut.

Now what

It's hard to find any good news in this earnings report. Attrition now appears to be a major problem for this business, which isn't great news given that the unemployment rate is so low and the company gets poor reviews on Glassdoor.com. Filling those vacancies with high-quality employees might prove to be very challenging. 

The acquisition of New Aera looks promising, but it's hard to get excited about the potential of the business, given that the company's business is performing so poorly.

I continue to believe that this company holds long-term potential, but there are clearly major issues going on that need to be sorted out. Until we get clear signs that the company's growth engine is back on track, I'm content to watch this story unfold from the sidelines.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inogen, Inc. Stock Quote
Inogen, Inc.
INGN
$25.84 (3.53%) $0.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
333%
 
S&P 500 Returns
116%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.